Immunovia AB (publ) (STO:IMMNOV)

Immunovia AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Revenue	0.69	0.93	1.58	1.15	0.84
Revenue	0.69	0.93	1.58	1.15	0.84
Revenue Growth (YoY)	-26.42%	-40.89%	37.55%	35.66%	133.15%
Cost of Revenue	0.14	-	6.68	4.21	-14.97
Gross Profit	0.55	0.93	-5.11	-3.07	15.81
Selling, General & Admin	77.73	94.48	148.3	162.97	162.09
Other Operating Expenses	0.95	3.21	1.56	0.26	1.4
Operating Expenses	81	111.11	291.58	188.14	182.55
Operating Income	-80.45	-110.17	-296.69	-191.21	-166.74
Interest Expense	-66.07	-1.86	-1.17	-1.6	-1.43
Interest & Investment Income	0.54	34.73	6.28	0.75	0.71
Currency Exchange Gain (Loss)	-	0.76	-17.87	23.97	11.5
Other Non Operating Income (Expenses)	0.07	-	0.01	-	-
EBT Excluding Unusual Items	-145.92	-76.54	-309.44	-168.09	-155.97
Pretax Income	-145.92	-76.54	-309.44	-168.09	-155.97
Net Income	-145.92	-76.54	-309.44	-168.09	-155.97
Net Income to Common	-145.92	-76.54	-309.44	-168.09	-155.97
Shares Outstanding (Basic)	344	83	39	23	23
Shares Outstanding (Diluted)	344	83	39	23	23
Shares Change (YoY)	316.79%	112.20%	72.02%	-	6.05%
EPS (Basic)	-0.42	-0.93	-7.95	-7.43	-6.89
EPS (Diluted)	-0.42	-0.93	-7.95	-7.43	-6.89
Free Cash Flow	-78.4	-96.75	-147.06	-176.84	-155.75
Free Cash Flow Per Share	-0.23	-1.17	-3.78	-7.81	-6.88
Gross Margin	80.15%	100.00%	-	-267.77%	1873.58%
Operating Margin	-11744.82%	-11833.94%	-18837.27%	-16699.48%	-19756.04%
Profit Margin	-21301.46%	-8221.38%	-19646.92%	-14680.52%	-18479.38%
Free Cash Flow Margin	-11445.26%	-10392.37%	-9336.95%	-15444.37%	-18453.67%
EBITDA	-78.13	-96.42	-170.03	-185.15	-161.1
D&A For EBITDA	2.33	13.75	126.66	6.06	5.64
EBIT	-80.45	-110.17	-296.69	-191.21	-166.74
Revenue as Reported	0.75	1.69	1.8	1.2	0.96

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.